Drug discovery & development with a focus on personalization and biologics
Protein drugs group work kick-off
TMED-929A
November 4, 2020
Michael Jeltsch (michael.jeltsch@helsinki.fi)
Slide 1 of 29
These slides: mjlab.fi/ddko
Source files: mjlab.fi/dd-files
Jeltsch Lab & UH
Creative Commons what?
Slide 2 of 29
This presentation: mjlab.fi/dd
Editable source files: mjlab.fi/dd-files
This work is licensed under the Creative Commons Attribution-Share Alike 4.0 International license. You are free:
Under the following conditions:
Some images are used under the “fair use” provision, which is legally unknown in Finland! Please consult the “image credit” link before using! Images without image credit link are all CC-licensed by the author.
Jeltsch Lab & UH
Tasks for this session
Tasks for this session
Slide 3 of 29
Introduction of teacher & participants
Short introduction of 9 possible drug choices
Instructions and agreement on “interim report” meetings
Group formation (4 groups of 4 students or 4 groups of 3 students + one 4-student-group), drug selection, group naming
What do you want to learn this course?
Jeltsch Lab & UH
Drug Development
Slide 4 of 29
Jeltsch Lab & UH
Different types of biologics
Slide 5 of 29
Vaccines
Gene therapy
Cell
therapy
Proteins
Transplants
Jeltsch Lab & UH
Focus on biologicals (protein drugs)
Slide 6 of 29
Jeltsch Lab & UH
(Protein) biologics
Slide 7 of 29
Interesting biological drugs
Jeltsch Lab & UH
Biological drug #1: Aranesp®
Slide 8 of 29
Aranesp® (Darbepoetin alfa)
image credits: TRANSMED
Jeltsch Lab & UH
Biological drug #1: Aranesp®
Slide 9 of 29
image credits: CiclismoItalia
Jeltsch Lab & UH
Biological drug #2: Avastin®
Slide 10 of 29
Avastin® (Bevacizumab)
Jeltsch Lab & UH
Folkman, Dvorak, Ferrara
Slide 11 of 29
1997
1971
Judah Folkman proposes the concept
of antiangiogenic tumor therapy
1992
1983
Napoleone Ferrara generates neutralizing
mouse antibodies against VEGF
Harold Dvorak isolates Vascular Endothelial Growth Factor (VEGF)
Clinical trials start with the humanized
anti-VEGF antibody (“bevacizumab”)
2004
Bevacizumab receives FDA approval
for treatment of colon cancer
Jeltsch Lab & UH
Biological drug #2: Avastin®
Slide 12 of 29
Jeltsch Lab & UH
Biological drug #3: Botox®
Slide 13 of 29
Botox® (OnabotulinumtoxinA)
Botulinum toxins (BTs)
Jeltsch Lab & UH
Biological drug #3: Botox®
Slide 14 of 29
Jeltsch Lab & UH
Biological drug #4: Eylea®
Slide 15 of 29
Eylea® (Aflibercept)
Jeltsch Lab & UH
Biological drug #4: Eylea®
Slide 16 of 29
image credits: ttfnrob
Jeltsch Lab & UH
Biological drug #5: Herceptin®
Slide 17 of 29
Herceptin® (Trastuzumab)
Antibody against ERBB2 (HER2)
Jeltsch Lab & UH
Biological drug #5: Herceptin®
Slide 18 of 29
Jeltsch Lab & UH
Biological drug #6: Humira®
Slide 19 of 29
Humira® (Adalimumab)
Antibody against TNF-⍺
Jeltsch Lab & UH
Biological drug #6: Humira®
Slide 20 of 29
Jeltsch Lab & UH
Biological drug #7: Insulin
Slide 21 of 29
Insulin
*The fact that pancreatic insulin-containing extracts were able to treat diabetes had been discovered three times independently before (by George Ludwig Zuelzer in 1906, Israel Kleiner in 1915, Nicolae Paulescu in 1916).
Jeltsch Lab & UH
Biological drug #7: Insulin
Slide 22 of 29
Jeltsch Lab & UH
Biological drug #8: Lymfactin®
Slide 23 of 29
Lymfactin®
The first drug for treating secondary lymphedema
Jeltsch Lab & UH
Biological drug #8: Lymfactin®
Slide 24 of 29
Jeltsch Lab & UH
Biological drug #9: Pegfilgrastim
Slide 25 of 29
Pegfilgrastim (GCSF)
Jeltsch Lab & UH
Biological drug #9: Pegfilgrastim
Slide 26 of 29
Image credits: Franziska Geiser
Jeltsch Lab & UH
Group work in breakout sessions
Slide 27 of 29
Jeltsch Lab & UH
Practicalities for the group work
Slide 28 of 29
Jeltsch Lab & UH
That’s all, folks!
That’s all, folks!
Slide 29 of 29
This presentation: mjlab.fi/ddko
Feedback: michael.jeltsch@helsinki.fi, michael@jeltsch.org
Lab: mjlab.fi (www.helsinki.fi/fi/tutkimusryhmat/lymphangiogeneesitutkimusta-ja-vasta-aineteknologia)
Private rumblings: jeltsch.org(/science)
Core facility: b3p.it.helsinki.fi
Jeltsch Lab & UH